Vegan versus traditional Mediterranean diet effects on cardiometabolic outcomes in women with fibromyalgia:FIBROVEG study.

NutritionMay 25, 2026 (epub)
Clinical ResearchCardiologyInternal Medicine (General)

Paula Marrero-Fernández, Ujué Fresán, Siobhan Nicaudie et al.

✦ AI-curated · Sources linked

In 30 seconds

The FIBROVEG study, a randomized controlled trial, assessed the effects of a vegan Mediterranean diet (VegMedDiet) versus a traditional Mediterranean diet (MedDiet) on cardiometabolic outcomes in 22 women with fibromyalgia over 6 weeks. The VegMedDiet resulted in a greater reduction in low-density lipoprotein cholesterol (LDL-C) by 21.2 mg/dL compared to the MedDiet.

Key findings

  • VegMedDiet reduced LDL-C by 21.2 mg/dL compared to MedDiet.
  • Triglycerides decreased by 27.4 mg/dL with VegMedDiet.
  • FIQ pain item score improved by 1.88 points with VegMedDiet.

Why it matters

This study highlights the potential of dietary interventions in managing cardiometabolic risk and fibromyalgia symptoms, suggesting that plant-based diets may offer significant benefits for affected individuals.

Source

PubMed · PMID 42320093

Published in Nutrition. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.